MA53881A - Dérivés de pyrido[4,3-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2 - Google Patents

Dérivés de pyrido[4,3-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2

Info

Publication number: MA53881A
Authority: MA; Morocco
Prior art keywords: idh1; oxazin; pyrido; inhibitors; derivatives
Prior art date: 2016-12-16

Application number

MA053881A

Other languages

English (en)

Inventor

Renato Alejandro Bauer

Serge Louis Boulet

Timothy Paul Burkholder

Raymond Gilmour

Patric James Hahn

Zoran Rankovic

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-12-16

Filing date

2017-12-08

Publication date

2022-04-27

2017-12-08 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2022-04-27 Publication of MA53881A publication Critical patent/MA53881A/fr

Links

101001042041 Bos taurus Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Proteins 0.000 title 1
101000960234 Homo sapiens Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 title 1
101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 title 1
102100039905 Isocitrate dehydrogenase [NADP] cytoplasmic Human genes 0.000 title 1
102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
UAQLXVHFTVTPBK-UHFFFAOYSA-N pyrido[4,3-d][1,3]oxazin-2-one Chemical class N=1C(OC=C2C=1C=CN=C2)=O UAQLXVHFTVTPBK-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Hematology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

MA053881A 2016-12-16 2017-12-08 Dérivés de pyrido[4,3-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2 MA53881A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201662435283P	2016-12-16	2016-12-16

Publications (1)

Publication Number	Publication Date
MA53881A true MA53881A (fr)	2022-04-27

Family

ID=60888651

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
MA47399A MA47399B1 (fr)	2016-12-16	2017-12-08	Dérivés de 7-phényléthylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2
MA053881A MA53881A (fr)	2016-12-16	2017-12-08	Dérivés de pyrido[4,3-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
MA47399A MA47399B1 (fr)	2016-12-16	2017-12-08	Dérivés de 7-phényléthylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2

Country Status (37)

Country	Link
US (3)	US11001596B2 (fr)
EP (2)	EP3763717B1 (fr)
JP (1)	JP6793836B2 (fr)
KR (1)	KR102276022B1 (fr)
CN (2)	CN115109075B (fr)
AU (2)	AU2017378060B2 (fr)
CA (1)	CA3045303C (fr)
CL (1)	CL2019001551A1 (fr)
CO (1)	CO2019005287A2 (fr)
CR (1)	CR20190252A (fr)
CY (1)	CY1123577T1 (fr)
DK (1)	DK3555105T3 (fr)
DO (1)	DOP2019000163A (fr)
EA (1)	EA036112B1 (fr)
EC (1)	ECSP19042682A (fr)
ES (2)	ES2835281T3 (fr)
HR (1)	HRP20201882T1 (fr)
HU (1)	HUE052067T2 (fr)
IL (1)	IL267236B (fr)
JO (1)	JOP20190142B1 (fr)
LT (1)	LT3555105T (fr)
MA (2)	MA47399B1 (fr)
MD (1)	MD3555105T2 (fr)
MX (1)	MX385562B (fr)
MY (1)	MY197313A (fr)
NZ (1)	NZ754115A (fr)
PE (1)	PE20190977A1 (fr)
PH (1)	PH12019501328B1 (fr)
PL (1)	PL3555105T3 (fr)
PT (1)	PT3555105T (fr)
RS (1)	RS61108B1 (fr)
SA (1)	SA519401897B1 (fr)
SI (1)	SI3555105T1 (fr)
TN (1)	TN2019000158A1 (fr)
UA (1)	UA123640C2 (fr)
WO (1)	WO2018111707A1 (fr)
ZA (1)	ZA201903125B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR102209667B1 (ko)	2014-09-19	2021-01-29	포르마 세라퓨틱스 인크.	돌연변이-아이소시트레이트 탈수소효소 저해제로서의 피리딘-2(1h)-온 퀴놀린 유도체
MX372964B (es)	2014-09-19	2020-03-27	Forma Therapeutics Inc	Derivados de fenil quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh)
AU2015317321B2 (en)	2014-09-19	2020-03-12	Forma Therapeutics, Inc.	Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
EP3201185B1 (fr)	2014-09-19	2018-11-21	Forma Therapeutics, Inc.	Dérivé de pyridinylquinolinone en tant qu'inhibiteurs de l'isocitrate déshydrogénase mutante
WO2016171755A1 (fr)	2015-04-21	2016-10-27	Forma Therapeutics, Inc.	Dérivés de phénylquinoléinone en tant qu'inhibiteurs de l'isocitrate déshydrogénase mutante
US9624216B2 (en)	2015-04-21	2017-04-18	Forma Therapeutics, Inc.	Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
JOP20190090B1 (ar)	2016-10-24	2023-03-28	Astrazeneca Ab	مشتقات 9،8،7،6-رابع هيدرو-3h-بيرازولو [4،3-f]أيزوكينولين مفيدة في علاج السرطان
JOP20190144A1 (ar)	2016-12-16	2019-06-16	Janssen Pharmaceutica Nv	إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
PH12019501328B1 (en) *	2016-12-16	2023-05-12	Lilly Co Eli	7-phenylethlamino-4h-pyrimido][4,5-d][1,3] oxazin-2-one compounds as mutant 1dh1 and 1dh2 inhibitors
JP7291077B2 (ja)	2016-12-16	2023-06-14	ヤンセンファーマシューティカエヌ．ベー．	Ｊａｋファミリーのキナーゼの低分子阻害物質
EP3689873B1 (fr)	2017-01-30	2022-09-14	Astrazeneca AB	Modulateurs du récepteur des oestrogènes
US20210196701A1 (en)	2018-05-16	2021-07-01	Forma Therapeutics, Inc.	Inhibiting mutant idh-1
US11497743B2 (en)	2018-05-16	2022-11-15	Forma Therapeutics, Inc.	Treating patients harboring an isocitrate dehydrogenase 1 (IDH-1) mutation
US11013733B2 (en)	2018-05-16	2021-05-25	Forma Therapeutics, Inc.	Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
WO2019222551A1 (fr)	2018-05-16	2019-11-21	Forma Therapeutics, Inc.	Formes solides de ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl) éthyl)amino)-1-méthyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
US11013734B2 (en)	2018-05-16	2021-05-25	Forma Therapeutics, Inc.	Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
US11738018B2 (en)	2018-05-16	2023-08-29	FORMA Therapeuetics, Inc.	Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
US11311527B2 (en)	2018-05-16	2022-04-26	Forma Therapeutics, Inc.	Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
TW202016110A (zh)	2018-06-15	2020-05-01	比利時商健生藥品公司	Ｊａｋ激酶家族之小分子抑制劑
ES3033669T3 (en)	2019-11-08	2025-08-06	Nerviano Medical Sciences Srl	Gem-disubstituted heterocyclic compounds and their use as idh inhibitors
AU2021241470B2 (en) *	2020-03-23	2023-12-14	Board Of Regents, The University Of Texas System	Combination therapy with a mutant IDH inhibitor and a Bcl-2 inhibitor
ES2981250T3 (es) *	2020-03-23	2024-10-08	Lilly Co Eli	Terapia combinada con un inhibidor de IDH mutante
IL296094A (en) *	2020-03-23	2022-11-01	Lilly Co Eli	Method for treating idh1 inhibitor-resistant subjects
JP7712955B2 (ja)	2020-04-24	2025-07-24	アストラゼネカ・アクチエボラーグ	癌の治療のための投薬レジメン
MX2022013258A (es)	2020-04-24	2022-11-14	Astrazeneca Ab	Formulaciones farmaceuticas.
CN115768775B (zh) *	2020-06-28	2024-10-25	微境生物医药科技(上海)有限公司	Idh突变体抑制剂及其用途
JP2023534991A (ja) *	2020-07-20	2023-08-15	イーライリリーアンドカンパニー	変異型ｉｄｈ１阻害剤、デオキシアデノシン類似体、及び白金剤を用いた併用療法
AU2022233254A1 (en)	2021-03-11	2023-10-26	Janssen Pharmaceutica Nv	Lorpucitinib for use in the treatment of jak mediated disorders
CN113588768B (zh) *	2021-05-18	2022-07-05	国家卫生健康委科学技术研究所	一种以分子图像方式定量组织内内源性代谢物的质谱方法
CN117460514A (zh) *	2021-06-09	2024-01-26	伊莱利利公司	用于治疗idh抑制剂耐药的对象的方法
US20240208978A1 (en) *	2021-06-15	2024-06-27	Wigen Biomedicine Technology (shanghai) Co., Ltd.	Idh mutant inhibitor and use thereof
CA3224704A1 (fr)	2021-08-13	2023-02-16	David Andrew Coates	Formes solides de 7-[[(1s)-1-[4-[(1s)-2-cyclopropyl-1-(4-prop-2-enoylpiperazin-1-yl)ethyl]phenyl]ethyl]amino]-1-ethyl-4h-pyrimido[4,5-d][1,3]oxazin-2-one
WO2023141087A1 (fr)	2022-01-19	2023-07-27	Eli Lilly And Company	Polythérapie avec un inhibiteur d'idh mutant

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2012313888B2 (en) *	2011-09-27	2016-03-31	Novartis Ag	3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
BR112015022483A2 (pt) *	2013-03-14	2017-07-18	Novartis Ag	3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante
WO2014147586A1 (fr) *	2013-03-22	2014-09-25	Novartis Ag	1-(2-(éthylamino)pyrimidin-4-yl)pyrrolidin-2-ones en tant qu'inhibiteurs du mutant idh
WO2016171755A1 (fr) *	2015-04-21	2016-10-27	Forma Therapeutics, Inc.	Dérivés de phénylquinoléinone en tant qu'inhibiteurs de l'isocitrate déshydrogénase mutante
WO2016171715A1 (fr) *	2015-04-24	2016-10-27	Halliburton Energy Services, Inc.	Procédé de fabrication de structures céramiques ou intermétalliques
JP6473270B2 (ja) *	2015-07-27	2019-02-20	イーライリリーアンドカンパニー	７−フェニルエチルアミノ−４ｈ−ピリミド［４，５−ｄ］［１，３］オキサジン−２−オン化合物及び変異体ｉｄｈ１阻害剤としてのそれらの使用
ES2814290T3 (es) *	2016-06-06	2021-03-26	Lilly Co Eli	Inhibidores de IDH1 mutante
PH12019501328B1 (en) *	2016-12-16	2023-05-12	Lilly Co Eli	7-phenylethlamino-4h-pyrimido][4,5-d][1,3] oxazin-2-one compounds as mutant 1dh1 and 1dh2 inhibitors

2017
- 2017-12-08 PH PH1/2019/501328A patent/PH12019501328B1/en unknown
- 2017-12-08 SI SI201730488T patent/SI3555105T1/sl unknown
- 2017-12-08 KR KR1020197016855A patent/KR102276022B1/ko active Active
- 2017-12-08 CA CA3045303A patent/CA3045303C/fr active Active
- 2017-12-08 NZ NZ754115A patent/NZ754115A/en unknown
- 2017-12-08 WO PCT/US2017/065246 patent/WO2018111707A1/fr not_active Ceased
- 2017-12-08 PT PT178228821T patent/PT3555105T/pt unknown
- 2017-12-08 MA MA47399A patent/MA47399B1/fr unknown
- 2017-12-08 JP JP2019532088A patent/JP6793836B2/ja active Active
- 2017-12-08 US US16/349,873 patent/US11001596B2/en active Active
- 2017-12-08 JO JOP/2019/0142A patent/JOP20190142B1/ar active
- 2017-12-08 PE PE2019001077A patent/PE20190977A1/es unknown
- 2017-12-08 EP EP20189241.1A patent/EP3763717B1/fr active Active
- 2017-12-08 ES ES17822882T patent/ES2835281T3/es active Active
- 2017-12-08 MY MYPI2019003350A patent/MY197313A/en unknown
- 2017-12-08 EA EA201991161A patent/EA036112B1/ru not_active IP Right Cessation
- 2017-12-08 EP EP17822882.1A patent/EP3555105B1/fr active Active
- 2017-12-08 TN TNP/2019/000158A patent/TN2019000158A1/en unknown
- 2017-12-08 HU HUE17822882A patent/HUE052067T2/hu unknown
- 2017-12-08 AU AU2017378060A patent/AU2017378060B2/en active Active
- 2017-12-08 HR HRP20201882TT patent/HRP20201882T1/hr unknown
- 2017-12-08 LT LTEP17822882.1T patent/LT3555105T/lt unknown
- 2017-12-08 MA MA053881A patent/MA53881A/fr unknown
- 2017-12-08 CN CN202210758386.7A patent/CN115109075B/zh active Active
- 2017-12-08 CR CR20190252A patent/CR20190252A/es unknown
- 2017-12-08 PL PL17822882T patent/PL3555105T3/pl unknown
- 2017-12-08 MD MDE20191188T patent/MD3555105T2/ro unknown
- 2017-12-08 MX MX2019006830A patent/MX385562B/es unknown
- 2017-12-08 CN CN201780078017.0A patent/CN110072867B/zh active Active
- 2017-12-08 UA UAA201905584A patent/UA123640C2/uk unknown
- 2017-12-08 DK DK17822882.1T patent/DK3555105T3/da active
- 2017-12-08 ES ES20189241T patent/ES2941631T3/es active Active
- 2017-12-08 RS RS20201429A patent/RS61108B1/sr unknown
2019
- 2019-05-17 ZA ZA2019/03125A patent/ZA201903125B/en unknown
- 2019-05-23 CO CONC2019/0005287A patent/CO2019005287A2/es unknown
- 2019-05-30 SA SA519401897A patent/SA519401897B1/ar unknown
- 2019-06-06 CL CL2019001551A patent/CL2019001551A1/es unknown
- 2019-06-11 IL IL267236A patent/IL267236B/en active IP Right Grant
- 2019-06-11 DO DO2019000163A patent/DOP2019000163A/es unknown
- 2019-06-14 EC ECSENADI201942682A patent/ECSP19042682A/es unknown
2020
- 2020-10-29 AU AU2020260493A patent/AU2020260493B2/en active Active
- 2020-11-25 CY CY20201101122T patent/CY1123577T1/el unknown
2021
- 2021-03-16 US US17/202,867 patent/US11629156B2/en active Active
- 2021-03-16 US US17/202,515 patent/US11649247B2/en active Active

Also Published As

Publication number	Publication date
US11629156B2 (en)	2023-04-18
EA036112B1 (ru)	2020-09-29
CL2019001551A1 (es)	2019-10-25
KR102276022B1 (ko)	2021-07-13
MD3555105T2 (ro)	2021-01-31
AU2020260493B2 (en)	2021-09-09
JP2020502157A (ja)	2020-01-23
RS61108B1 (sr)	2020-12-31
JOP20190142B1 (ar)	2023-03-28
PL3555105T3 (pl)	2021-05-17
CN110072867A (zh)	2019-07-30
WO2018111707A1 (fr)	2018-06-21
US11649247B2 (en)	2023-05-16
CR20190252A (es)	2019-08-26
ES2835281T3 (es)	2021-06-22
CN115109075A (zh)	2022-09-27
CN110072867B (zh)	2022-07-08
IL267236A (en)	2019-08-29
SA519401897B1 (ar)	2022-07-28
ES2941631T3 (es)	2023-05-24
MY197313A (en)	2023-06-13
EP3763717A1 (fr)	2021-01-13
AU2020260493A1 (en)	2020-11-26
US11001596B2 (en)	2021-05-11
US20210206780A1 (en)	2021-07-08
SI3555105T1 (sl)	2020-12-31
UA123640C2 (uk)	2021-05-05
DK3555105T3 (da)	2020-11-09
CY1123577T1 (el)	2022-03-24
MA47399B1 (fr)	2021-02-26
PE20190977A1 (es)	2019-07-09
BR112019009648A2 (pt)	2019-09-10
MX385562B (es)	2025-03-18
TN2019000158A1 (en)	2020-10-05
MX2019006830A (es)	2019-08-22
KR20190077539A (ko)	2019-07-03
IL267236B (en)	2020-08-31
AU2017378060A1 (en)	2019-05-30
US20200079791A1 (en)	2020-03-12
HUE052067T2 (hu)	2021-04-28
EP3555105A1 (fr)	2019-10-23
CN115109075B (zh)	2024-09-20
EP3555105B1 (fr)	2020-10-28
CO2019005287A2 (es)	2019-05-31
PT3555105T (pt)	2020-12-21
CA3045303C (fr)	2022-05-17
DOP2019000163A (es)	2019-07-15
LT3555105T (lt)	2021-01-11
ZA201903125B (en)	2024-08-28
CA3045303A1 (fr)	2018-06-21
PH12019501328B1 (en)	2023-05-12
HRP20201882T1 (hr)	2021-01-22
EA201991161A1 (ru)	2019-11-29
JP6793836B2 (ja)	2020-12-02
PH12019501328A1 (en)	2020-02-24
ECSP19042682A (es)	2019-06-30
JOP20190142A1 (ar)	2019-06-13
EP3763717B1 (fr)	2023-03-08
US20210230185A1 (en)	2021-07-29
AU2017378060B2 (en)	2020-09-03
MA47399A (fr)	2019-10-23
NZ754115A (en)	2021-07-30

Publication	Publication Date	Title
MA47123A (fr)	2021-03-17	Dérivés de benzooxazole en tant qu'mmunomodulateurs
IL267236B (en)	2020-08-31	Derivatives of 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one as 1idh and 2idh mutant inhibitors
MA46339A (fr)	2019-08-07	Dérivés de cyanopyrrolidine ayant une activité en tant qu'inhibiteurs de l'usp 30
DK3558990T3 (da)	2022-09-12	Tetrahydroimidazo[4,5-c]pyridinderivater som pd-l1 internaliseringsinducere
EA201791692A1 (ru)	2018-01-31	4H-ПИРРОЛО[3,2-c]ПИРИДИН-4-ОНОВЫЕ ПРОИЗВОДНЫЕ
MA46470A (fr)	2019-08-14	1h-imidazo[4,5-b]pyridin-2(3h)-ones substituées et leur utilisation en tant que modulateurs du récepteur glun2b
EP3416964A4 (fr)	2019-09-18	Dérivés de carboxamide utiles en tant qu'inhibiteurs de rsk
MX390630B (es)	2025-03-21	Derivados de maitansinoide, conjugados de los mismos y metodos de uso.
IL263947B (en)	2022-10-01	Compositions and methods for making benzylisoquinoline alkaloids, morphinan alkaloids, thebaine, and derivatives thereof
HUE053027T2 (hu)	2021-06-28	Stabilizált, szolúbilis prefúziós RSV F fehérje, RSV-fertõzés megelõzésében történõ alkalmazásra
MX386328B (es)	2025-03-18	Derivados de maitansinoide, conjugados de los mismos, y metodos de uso.
MA46264A (fr)	2019-07-31	Dérivés pyrazolo[1,5-a]pyridine et leur utilisation en tant qu'agents de lutte antiparasitaire
ME03672B (fr)	2020-10-20	1h-pyrazolo [4,3-b]pyridines en tant qu'inhibiteurs de pde1
MA54448A (fr)	2021-10-20	Dérivés naphthyridine et quinoléine en tant qu'inhibiteurs de alk5
EP3515914A4 (fr)	2020-04-15	Nouvelles imidazo[1,5-a]pyridines substituées en position 5 ou 8 en tant qu'indoleamine et/ou tryptophane 2,3-dioxygénases
EP3328379A4 (fr)	2019-06-19	Dérivés bis-hétéroaryliques en tant que modulateurs de l'agrégation des protéines
EP3402793A4 (fr)	2019-10-09	Dérivés de pyridazine en tant qu'activateurs d'eaat2
MX2018002416A (es)	2018-11-29	Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos.
EP3487851A4 (fr)	2019-12-25	Dérivés de l'aminopyridine et leur utilisation en tant qu'inhibiteurs sélectifs d'alk-2
MA52722A (fr)	2021-04-14	Dérivés d'oxazine en tant qu'inhibiteurs de bêta-sécrétase et procédés d'utilisation
MA51133A (fr)	2020-10-21	Dérivés de pyrrole utilisés en tant qu'inhibiteurs d'acc
UY35747A (es)	2015-04-30	Derivados sustituidos de fenilalanina
EP3426636A4 (fr)	2020-01-01	Hétérocycles substitués en tant qu'agents de ciblage de c-myc
MA53432A (fr)	2021-06-30	Imidazo[1,2-b]pyridazines utilisées en tant qu'inhibiteurs de trk
MA47593A (fr)	2020-01-01	Dérivés de 1, 4, 6-trisubstitué-2-alkyl-1h-benzo[d]imidazole en tant qu'inhibiteurs de dihydroorotate oxygénase